Massive study aims to predict deadly clots in liver patients

NCT ID NCT07422701

Not yet recruiting Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow about 2,500 adults with liver cirrhosis to learn who gets dangerous blood clots in the liver's main vein, how these clots affect survival, and whether blood-thinner medications are safe and helpful. Participants receive no experimental treatment—just routine care and checkups over two years. The goal is to give doctors better tools to predict and manage this complication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS PORTAL VEIN THROMBOSIS

Contacts and locations

Locations

Beijing YouAn Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Hengshui No. 3 People's Hospital

Hengshui, Hebei, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Qingdao No.6 People's Hospital

Qingdao, Shandong, China
Qinhuangdao No. 3 People's Hospital

Qinhuangdao, Hebei, China
Shenzhen Third People's Hospital

Shenzhen, Guangdong, China
Wuxi No.5 People's Hospital

Wuxi, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.